The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biologic agents and conversion therapy

Axel F Grothey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent findings in studies of chemotherapy in metastatic colorectal cancer include the apparent ability of the presence of mutated K-ras to predict the absence of response to epidermal growth factor receptor (EGFR) inhibitors, the lack of benefit of combining panitumumab and bevacizumab in first-line treatment, the benefits of maintenance therapy versus chemotherapy-free intervals, and the suggested benefit of continuing bevacizumab treatment beyond first disease progression. In the setting of liver metastases, recent data indicate a reduced risk of disease progression with perioperative chemotherapy in patients with resectable disease (albeit at the cost of increased postoperative complications) and potential roles for chemotherapy and biologic therapy in converting initially unresectable disease to resectable disease.

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalCommunity Oncology
Volume5
Issue number6 SUPPL. 6
StatePublished - Jun 2008

Fingerprint

Biological Factors
Colorectal Neoplasms
Drug Therapy
Disease Progression
Biological Therapy
Therapeutics
Epidermal Growth Factor Receptor
Neoplasm Metastasis
Liver
Bevacizumab

ASJC Scopus subject areas

  • Oncology

Cite this

The role of chemotherapy in stage IV colorectal cancer : Focus on combinations with biologic agents and conversion therapy. / Grothey, Axel F.

In: Community Oncology, Vol. 5, No. 6 SUPPL. 6, 06.2008, p. 3-8.

Research output: Contribution to journalArticle

@article{1e50b1c233354081b3f13a054e92c90d,
title = "The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biologic agents and conversion therapy",
abstract = "Recent findings in studies of chemotherapy in metastatic colorectal cancer include the apparent ability of the presence of mutated K-ras to predict the absence of response to epidermal growth factor receptor (EGFR) inhibitors, the lack of benefit of combining panitumumab and bevacizumab in first-line treatment, the benefits of maintenance therapy versus chemotherapy-free intervals, and the suggested benefit of continuing bevacizumab treatment beyond first disease progression. In the setting of liver metastases, recent data indicate a reduced risk of disease progression with perioperative chemotherapy in patients with resectable disease (albeit at the cost of increased postoperative complications) and potential roles for chemotherapy and biologic therapy in converting initially unresectable disease to resectable disease.",
author = "Grothey, {Axel F}",
year = "2008",
month = "6",
language = "English (US)",
volume = "5",
pages = "3--8",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "6 SUPPL. 6",

}

TY - JOUR

T1 - The role of chemotherapy in stage IV colorectal cancer

T2 - Focus on combinations with biologic agents and conversion therapy

AU - Grothey, Axel F

PY - 2008/6

Y1 - 2008/6

N2 - Recent findings in studies of chemotherapy in metastatic colorectal cancer include the apparent ability of the presence of mutated K-ras to predict the absence of response to epidermal growth factor receptor (EGFR) inhibitors, the lack of benefit of combining panitumumab and bevacizumab in first-line treatment, the benefits of maintenance therapy versus chemotherapy-free intervals, and the suggested benefit of continuing bevacizumab treatment beyond first disease progression. In the setting of liver metastases, recent data indicate a reduced risk of disease progression with perioperative chemotherapy in patients with resectable disease (albeit at the cost of increased postoperative complications) and potential roles for chemotherapy and biologic therapy in converting initially unresectable disease to resectable disease.

AB - Recent findings in studies of chemotherapy in metastatic colorectal cancer include the apparent ability of the presence of mutated K-ras to predict the absence of response to epidermal growth factor receptor (EGFR) inhibitors, the lack of benefit of combining panitumumab and bevacizumab in first-line treatment, the benefits of maintenance therapy versus chemotherapy-free intervals, and the suggested benefit of continuing bevacizumab treatment beyond first disease progression. In the setting of liver metastases, recent data indicate a reduced risk of disease progression with perioperative chemotherapy in patients with resectable disease (albeit at the cost of increased postoperative complications) and potential roles for chemotherapy and biologic therapy in converting initially unresectable disease to resectable disease.

UR - http://www.scopus.com/inward/record.url?scp=46049107695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049107695&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:46049107695

VL - 5

SP - 3

EP - 8

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 6 SUPPL. 6

ER -